The Science of Hyaluronidase — Dissolving Dermal Fillers Safely

Last updated: 5 March 2026

One of the most significant safety advantages of hyaluronic acid (HA) dermal fillers is their reversibility. The enzyme hyaluronidase can dissolve HA fillers quickly and effectively, making it an essential tool in aesthetic medicine for managing complications, correcting unsatisfactory results, and ensuring patient safety. This comprehensive guide explores the science behind hyaluronidase, how it works, when it is used, and what patients in the UK should know.

What Is Hyaluronidase?

Hyaluronidase is a naturally occurring enzyme that breaks down hyaluronic acid by cleaving the glycosidic bonds within the HA polymer chain. In the human body, hyaluronidase enzymes play a role in normal tissue remodelling, sperm penetration of the ovum, and the spread of infections and venoms (which is why it was originally called “spreading factor”).

In clinical practice, pharmaceutical-grade hyaluronidase has been used since the 1950s to enhance the absorption and dispersion of other injected drugs. Its use in aesthetic medicine for dissolving HA fillers has become standard practice over the past 15 years. In the UK, the most commonly used preparation is Hyalase (hyaluronidase 1,500 IU, manufactured by Wockhardt), which is a prescription-only medicine.

How Hyaluronidase Works

When injected into tissue containing HA filler, hyaluronidase rapidly breaks down the cross-linked hyaluronic acid gel into smaller fragments. These fragments are then absorbed and metabolised by the body through normal physiological pathways. The process begins within minutes, with visible reduction in filler volume often apparent within 24–48 hours.

The enzyme works through a process called enzymatic hydrolysis, specifically cleaving β-1,4-glycosidic bonds between N-acetylglucosamine and glucuronic acid residues in the HA chain. This is the same mechanism by which the body naturally breaks down its own hyaluronic acid during tissue remodelling.

Factors Affecting Dissolution Speed

• Filler cross-linking density — more heavily cross-linked fillers (e.g., Juvéderm Voluma) require more hyaluronidase and longer dissolution times than lighter fillers
• Volume of filler — larger volumes require more enzyme and may need repeat treatments
• Age of filler — recently placed filler dissolves faster than older, more integrated filler
• Injection technique — direct injection into the filler bolus is more effective than peri-filler injection
• Hyaluronidase dose — higher doses produce faster, more complete dissolution

Clinical Indications for Hyaluronidase

Emergency Use: Vascular Occlusion

The most critical indication for hyaluronidase is vascular occlusion — when filler accidentally compresses or enters a blood vessel, blocking blood flow. This is a medical emergency that can lead to tissue necrosis (death) or, in the most serious cases, blindness if the ophthalmic artery is affected. Immediate injection of hyaluronidase into and around the affected area can dissolve the obstructing filler and restore blood flow.

Signs of vascular occlusion include intense pain disproportionate to the procedure, blanching (whitening) of the skin, livedo reticularis (net-like purple discolouration), visual changes (if periorbital vessels are affected), and delayed capillary refill in the affected area. If any of these signs occur during or after filler treatment, hyaluronidase should be administered immediately.

Elective Use: Correction and Revision

• Overfilling — too much product placed, creating an unnatural appearance
• Asymmetry — uneven results requiring reduction on one side
• Migration — filler that has moved from the intended placement site
• Tyndall effect — blue-grey discolouration when filler is placed too superficially
• Nodules or lumps — palpable irregularities in the filler
• Patient preference — the patient simply wishes to return to their pre-treatment appearance

Complication Management

• Biofilm-associated inflammation — dissolving the filler removes the substrate for bacterial colonisation
• Delayed hypersensitivity — removing the filler eliminates the antigenic stimulus
• Granulomatous reactions — filler dissolution can resolve or reduce inflammatory nodules

The Dissolution Process: What to Expect

Stage	Timeline	What Happens
Pre-treatment	Before injection	Allergy history reviewed; patch test considered for high-risk patients
Injection	5–15 minutes	Hyaluronidase injected into filler; may cause temporary stinging
Immediate effect	Minutes to hours	Enzymatic breakdown begins; area may swell temporarily
Early resolution	24–48 hours	Significant reduction in filler volume; swelling subsides
Full effect	48–72 hours	Maximum dissolution achieved; area assessed for completeness
Follow-up	1–2 weeks	Review appointment; repeat treatment if needed

Safety Considerations

Allergy and Hypersensitivity

True allergy to hyaluronidase is rare but possible. Patients with known allergies to bee or wasp stings may have a higher risk, as some hyaluronidase preparations are derived from bovine sources that share antigenic properties with hymenoptera venom. In the UK, practitioners are advised to have appropriate resuscitation equipment available when administering hyaluronidase. Some clinics perform a patch test (intradermal injection of a small dose) before proceeding with larger volumes, particularly in emergency situations where a rapid risk assessment is needed.

Effect on Natural Hyaluronic Acid

One common patient concern is whether hyaluronidase will dissolve their natural hyaluronic acid. While the enzyme does temporarily affect native HA, the body rapidly replenishes its own hyaluronic acid stores. Studies have shown that native HA levels return to normal within approximately 48–72 hours. In practice, this means patients may notice temporary dryness or slight volume loss beyond the filler area, which resolves quickly.

Re-treatment After Dissolution

Patients who wish to have fillers re-placed after dissolution are generally advised to wait 2–4 weeks. This allows the tissue to fully recover, any residual enzyme activity to cease, and natural HA levels to normalise. Re-injecting too soon can result in rapid breakdown of the new filler.

Regulation and Access in the UK

Hyaluronidase (Hyalase) is a prescription-only medicine (POM) in the UK, meaning it can only be prescribed by a doctor, dentist, nurse prescriber, or pharmacist prescriber. This is an important safety consideration when choosing a filler practitioner — non-prescribers may not have legal access to hyaluronidase, leaving patients without a safety net if complications occur.

The JCCP, Save Face, and other professional bodies strongly recommend that all practitioners performing HA filler treatments either hold prescribing rights themselves or have an established protocol with a prescriber for immediate access to hyaluronidase. This should be verified during your consultation.

Frequently Asked Questions

Hyaluronidase is a cornerstone of safety in aesthetic medicine. Its existence as a reliable reversal agent is one of the strongest arguments for choosing hyaluronic acid fillers as a first-line injectable treatment. Understanding its role empowers patients to make informed decisions and gives confidence that, if any issue arises, effective treatment is available.

Have questions about filler dissolution? Contact our team for confidential advice. Related reading: Biofilm Complications in Dermal Fillers and Managing Bruising After Injectables.